Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington,	D.C.	20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average bu	urden							
hours per response:	0.5							

1. Name and Address of Reporting Person*  Kathiresan Sekar					2. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc. [ VERV ]								(Check all applicable)  X Director			10% Own			
(Last) (First) (Middle) C/O VERVE THERAPEUTICS 500 TECHNOLOGY SQUARE, SUITE 901				3. Date of Earliest Transaction (Month/Day/Year) 07/19/2022									X Officer (give title below)  Chief Executive Officer						
(Street)	IDGE M	IA	02139		4.	If Ame	endme	ent, Date o	of Origin	al File	d (Month/Da	ay/Year)		Line	X Form f	iled by C	one Rep	g (Check / orting Per n One Re	son
(City)	(S	state)	(Zip)												1 01001				
		Tak	ole I - No	on-Deri	vativ	e Se	curi	ties Ac	quired	l, Di	sposed o	f, or Be	nefic	iall	y Owned				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea		Execution Date,		Transaction Di		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a 5)					у	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code V Amount (A) or (D) Price		•	Transactio (Instr. 3 an				(1130.4)					
Common	Stock			07/19	/2022	2			M		50,000	A	\$1.	.39	367,8	39	I	)	
Common	Stock			07/19	/2022	!			<b>S</b> <sup>(1)</sup>		50,000	D	\$29	9.9	317,8	339	I	)	
Common	Stock														240,9	97	:	I	Kathiresan Family 2021 Irrevocable Trust
Common Stock													80,997		I		Sekar Kathiresan 2021 Irrevocable Trust		
			Table II						,		oosed of, convertil			•	Owned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  Security  3. Transaction Date (Month/Day/Year) if any (Month/Day/Year)		ned 4. n Date, Transacti Code (Ins		action	5. Number ction of		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title of Sect Underly Derivat			7. Title an of Securit Underlyin Derivative	itle and Amou		8. Price of Derivative Security (Instr. 5)	derivat Securit Benefic Owned Follow Report	tive ties cially l ing ed ction(s)	10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficia Ownersh ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (right to buy)	\$1.39	07/19/2022			M			50,000	(2)		04/14/2029	Common Stock	50,0	000	\$0.00	217	,425	D	

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.
- 2. The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.

## Remarks:

/s/ Andrew Ashe, as Attorneyin-Fact for Sekar Kathiresan

07/21/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).